New cocktail aims to shrink head and neck tumors before surgery

NCT ID NCT07457346

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a new combination of drugs—imaxitinib, chemotherapy, and immunotherapy—given before surgery for advanced head and neck cancer. The goal is to see if this approach can shrink tumors more effectively, making surgery easier or possible for patients whose cancer is hard to remove. About 76 participants will receive the treatment and be monitored for tumor response and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
imaxitinib (a JAK inhibitor) combined with chemotherapy (cisplatin, nab-paclitaxel) and immunotherapy (adebrelimab)
What this could lead to
If successful, this combination could shrink advanced head and neck tumors before surgery, potentially making surgery easier or possible for more patients.
What could go wrong
This is a small, early-phase trial (76 people) with no results yet. The drug combo may cause side effects or not work better than current treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • 2nd Affiliated Hospital, School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.